Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea · Delayed Price · Currency is KRW 173,500
+8,100 (4.90%)
Last updated: Nov 26, 2025, 11:36 AM KST
Daewoong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 1,541,649 | 1,422,683 | 1,375,329 | 1,280,092 | 1,152,976 | 1,055,424 | Upgrade |
Other Revenue | -0 | -0 | -0 | -0 | -0 | - | Upgrade |
| 1,541,649 | 1,422,683 | 1,375,329 | 1,280,092 | 1,152,976 | 1,055,424 | Upgrade | |
Revenue Growth (YoY) | 8.82% | 3.44% | 7.44% | 11.03% | 9.24% | -5.21% | Upgrade |
Cost of Revenue | 740,790 | 689,472 | 688,221 | 641,997 | 609,227 | 609,435 | Upgrade |
Gross Profit | 800,859 | 733,211 | 687,108 | 638,095 | 543,749 | 445,989 | Upgrade |
Selling, General & Admin | 417,416 | 396,260 | 376,109 | 366,091 | 315,434 | 299,358 | Upgrade |
Research & Development | 173,465 | 171,290 | 171,573 | 163,602 | 127,269 | 115,218 | Upgrade |
Amortization of Goodwill & Intangibles | 4,178 | 4,676 | 1,919 | 1,963 | 2,072 | 2,351 | Upgrade |
Other Operating Expenses | 4,835 | 4,476 | 4,382 | 4,297 | 3,554 | 3,531 | Upgrade |
Operating Expenses | 611,426 | 587,973 | 565,990 | 542,297 | 455,020 | 429,009 | Upgrade |
Operating Income | 189,434 | 145,238 | 121,118 | 95,797 | 88,729 | 16,980 | Upgrade |
Interest Expense | -11,325 | -6,986 | -13,603 | -8,406 | -10,248 | -10,610 | Upgrade |
Interest & Investment Income | 3,103 | 5,094 | 3,099 | 4,135 | 2,569 | 3,423 | Upgrade |
Earnings From Equity Investments | -35,522 | -23,153 | 29,977 | -374.54 | 257.52 | -355.37 | Upgrade |
Currency Exchange Gain (Loss) | -1,033 | 6,261 | -1,705 | -40.31 | 3,246 | -6,548 | Upgrade |
Other Non Operating Income (Expenses) | 9,650 | -28,994 | -13,423 | -43,639 | -69,962 | 8,622 | Upgrade |
EBT Excluding Unusual Items | 154,307 | 97,459 | 125,462 | 47,473 | 14,591 | 11,511 | Upgrade |
Gain (Loss) on Sale of Investments | -25,276 | -24,951 | 130.67 | -4,171 | 8,308 | 2,622 | Upgrade |
Gain (Loss) on Sale of Assets | -465.97 | -465.97 | -1,221 | 246.4 | -1,029 | 7,530 | Upgrade |
Asset Writedown | -15,492 | -15,492 | -2,372 | -5,219 | -2,109 | -8,103 | Upgrade |
Pretax Income | 113,073 | 56,550 | 121,999 | 38,330 | 19,761 | 13,559 | Upgrade |
Income Tax Expense | 17,381 | 33,204 | 1,996 | -833.51 | -10,323 | -10,589 | Upgrade |
Earnings From Continuing Operations | 95,692 | 23,347 | 120,003 | 39,163 | 30,084 | 24,148 | Upgrade |
Minority Interest in Earnings | -2,507 | 1,388 | 1,736 | 3,076 | -5,578 | -11,395 | Upgrade |
Net Income | 93,185 | 24,735 | 121,739 | 42,240 | 24,506 | 12,753 | Upgrade |
Net Income to Common | 93,185 | 24,735 | 121,739 | 42,240 | 24,506 | 12,753 | Upgrade |
Net Income Growth | -10.03% | -79.68% | 188.21% | 72.37% | 92.15% | -42.05% | Upgrade |
Shares Outstanding (Basic) | 12 | 12 | 11 | 11 | 11 | 11 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 11 | 11 | 11 | 11 | Upgrade |
Shares Change (YoY) | 0.01% | 0.71% | 3.21% | 0.59% | 3.21% | 3.31% | Upgrade |
EPS (Basic) | 8098.35 | 2149.65 | 10655.61 | 3815.95 | 2226.87 | 1196.10 | Upgrade |
EPS (Diluted) | 8098.35 | 2149.65 | 10655.61 | 3815.95 | 2226.87 | 1196.10 | Upgrade |
EPS Growth | -10.04% | -79.83% | 179.24% | 71.36% | 86.18% | -43.90% | Upgrade |
Free Cash Flow | -19,015 | -103,653 | 26,671 | 52,988 | 10,906 | 74,495 | Upgrade |
Free Cash Flow Per Share | -1652.48 | -9008.37 | 2334.47 | 4786.97 | 991.08 | 6986.64 | Upgrade |
Dividend Per Share | 600.000 | 600.000 | - | - | - | - | Upgrade |
Gross Margin | 51.95% | 51.54% | 49.96% | 49.85% | 47.16% | 42.26% | Upgrade |
Operating Margin | 12.29% | 10.21% | 8.81% | 7.48% | 7.70% | 1.61% | Upgrade |
Profit Margin | 6.04% | 1.74% | 8.85% | 3.30% | 2.13% | 1.21% | Upgrade |
Free Cash Flow Margin | -1.23% | -7.29% | 1.94% | 4.14% | 0.95% | 7.06% | Upgrade |
EBITDA | 239,829 | 194,217 | 164,915 | 135,492 | 129,613 | 57,861 | Upgrade |
EBITDA Margin | 15.56% | 13.65% | 11.99% | 10.59% | 11.24% | 5.48% | Upgrade |
D&A For EBITDA | 50,395 | 48,978 | 43,797 | 39,695 | 40,883 | 40,882 | Upgrade |
EBIT | 189,434 | 145,238 | 121,118 | 95,797 | 88,729 | 16,980 | Upgrade |
EBIT Margin | 12.29% | 10.21% | 8.81% | 7.48% | 7.70% | 1.61% | Upgrade |
Effective Tax Rate | 15.37% | 58.72% | 1.64% | - | - | - | Upgrade |
Advertising Expenses | - | 74,101 | 79,245 | 80,587 | 59,081 | 51,192 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.